LifeVantage: A New CEO, a GLP-1 Hangover, and a Bet on Shopify

With revenue down 25% as MINDBODY fades, the company looks to a new leader, an upgraded e-commerce stack, and a VIP incentive program to reignite growth.

LFVN · Earnings Call · 2026-05-06

LifeVantage's fiscal Q3 2026 was a bruising quarter. “For 2026, we delivered net revenue of $43.7 million, which was down 25.2% compared to $58.4 million in 2025. The decrease was primarily driven by a decline in sales of our MINDBODY GLP-1 system, partially offset by sales of LoveBiome, which we acquired in October 2025.” — Carl Aure, Chief Financial Officer · 2026-05-06 The gut health and weight-management pivot, once a growth engine, is now the biggest drag. The GLP-1 market has become intensely competitive, with synthetic options dominating the conversation. As the company's LoveBiome product line ramps, the legacy MINDBODY franchise is losing steam. The numbers paint a clear picture: Total revenue fell to $44M, down 25% year-over-year, with a 29% decline in the Americas. Gross margin contracted to 79% from 81%, reflecting higher shipping and inventory charges. Adjusted operating income came in at just $1.8M.

The Strategic Reset

The board has responded with decisive leadership changes.

The world belongs to the discontented. Well, let me assure you that we are not content, and I pledge to work tirelessly with this team on behalf of all of our stakeholders to improve the results.
Michael Beindorff, Interim Chief Executive Officer · 2026-05-06

That was interim CEO Michael Beindorff, who took over after Steve Fife's retirement. The company has already appointed Terrence Moorhead, a seasoned direct-selling executive, to take the helm in August. Beyond the C-suite, the company is investing in its digital backbone. “We are making a significant investment in upgrading our e-commerce platform. The launch of Shopify along with a totally revamped and upgraded back-office system will dramatically improve both our customers' and our consultants' e-commerce experience with LifeVantage Corporation from end to end.” — Michael Beindorff, Interim Chief Executive Officer · 2026-05-06 This is not just a tech upgrade; it's a bet on a modern direct-selling model. The company is also launching its first-ever 12-month incentive program for consultants — the VIP bonus — designed to reward growth and leadership. The integration of LoveBiome, acquired last October, is still underway. The hope is that P84, a microbiome activator, will become a third hero product alongside Protandim and Collagen. As Steve Fife described it during the acquisition announcement: “it does regulate, repair and restore the gut microbiome” — Steven Fife, President and Chief Executive Officer · 2025-09-04

A Familiar Competitive Battle

The core issue is the GLP-1 landscape. In prior quarters, management argued that the natural, science-backed approach would win over synthetic drugs. As Steve Fife put it in February: “We believe that because of our solution. There are we still when you look at our clinical studies, our science, and our results, and you layer on top of that a natural solution versus it doesn't matter really if it's an injectable or a pill that you're taking.” — Steve Fife, President and Chief Executive Officer · 2026-02-04 Now, with the market crowded and insurance-driven dynamics, that bet is under pressure. CFO Carl Aure admitted the guidance reflects "the competitive dynamics in the GLP-1 market." The company is doubling down on its foundation: “We are seeing consultants going back to the foundation of their own business. They are excited about Protandim, about Collagen, about Healthy Glow” — Kristen Cunningham, Chief Sales Officer · 2026-05-06 — a shift back to its core nutritional products while the GLP-1 story matures.

Financial Resilience and Market Signal

Despite the top-line slump, the balance sheet remains clean: $12.5M cash and zero debt. Cash from operations has been volatile, but management expects Q4 to generate ~$5M. The company repurchased shares and raised its dividend by 11%. Free cash flow turned positive in the quarter after a negative Q4. The stock has been on a wild ride: up 61% in the last 90 days, but still 37.5% below its June peak. The market seems to be pricing in a turnaround under new leadership, but execution risk is high. The coming quarters will test whether the new leadership can stabilize the field organization and convert the Shopify investment into tangible conversion gains.